<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increasing evidence suggests that <z:chebi fb="0" ids="41423">celecoxib</z:chebi>, a COX-2 inhibitor with potent anticancer activity exerts its effects not only through COX-2, but also through COX-2-independent mechanisms </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, we hypothesized that endoplasmic reticulum stress (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ERS</z:e>) is involved in the up-regulation of VEGF expression induced by <z:chebi fb="0" ids="41423">celecoxib</z:chebi> in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> HCT116 cells and that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ERS</z:e> is a major mechanism by which <z:chebi fb="0" ids="41423">celecoxib</z:chebi> triggers <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell <z:hpo ids='HP_0011420'>death</z:hpo> in a COX-2-independent manner </plain></SENT>
<SENT sid="2" pm="."><plain>HCT116 cells, which do not express COX-2, were cultured in the absence or presence of <z:chebi fb="0" ids="41423">celecoxib</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>VEGF expression was detected by quantitative real-time RT-PCR and western blotting </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ERS</z:e> triggered by <z:chebi fb="0" ids="41423">celecoxib</z:chebi> was determined by expression of ER chaperones and other markers </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="3" ids="53317">PBA</z:chebi> (an inhibitor of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ERS</z:e>) and GRP78 overexpression were both used to prevent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ERS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was evaluated by TUNEL assay and fluorescence activated cell sorting </plain></SENT>
<SENT sid="7" pm="."><plain>In HCT116 cells, <z:chebi fb="0" ids="41423">celecoxib</z:chebi> increased VEGF production with time-course and dose-response curves similar to those observed for the increase of the ER chaperone, GRP78 </plain></SENT>
<SENT sid="8" pm="."><plain>CHOP, a marker of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ERS</z:e> involved in <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, was also increased by <z:chebi fb="0" ids="41423">celecoxib</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Moreover, <z:chebi fb="0" ids="41423">celecoxib</z:chebi> promoted cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="10" pm="."><plain>Both <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and up-regulation of VEGF were prevented by protecting cells from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ERS</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="41423">Celecoxib</z:chebi> induces cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and up-regulation of VEGF in HCT116 cells via activation of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ERS</z:e> response </plain></SENT>
<SENT sid="12" pm="."><plain>Further studies are necessary to evaluate whether the combination of <z:chebi fb="0" ids="41423">celecoxib</z:chebi> with anti-VEGF agents is a promising therapeutic modality for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>